GE HealthCare to Acquire icometrix, Expanding AI-Powered MRI for Neurological Care
GE HealthCare has announced plans to acquire icometrix, a Belgium-based company specializing in AI-driven brain imaging analysis, to strengthen its neurology portfolio and address the rising demand for MRI in personalized treatment planning. The deal, which remains subject to regulatory approvals and closing conditions, reflects GE HealthCare’s strategy to broaden precision care solutions across the neuroimaging landscape.
Founded in 2011, icometrix is best known for its icobrain platform, which extracts and analyzes data from brain MRI scans to support diagnosis and treatment planning for conditions such as Alzheimer’s disease, multiple sclerosis, dementia, epilepsy, stroke, and traumatic brain injury. One of its flagship offerings, icobrain aria, is the first FDA-cleared computer-aided detection and diagnosis solution for identifying and quantifying Amyloid Related Imaging Abnormalities (ARIA)—a common side effect of new anti-amyloid therapies used in Alzheimer’s treatment.
The acquisition comes at a critical time. According to the Alzheimer’s Association, the number of individuals living with Alzheimer’s is projected to double by 2050. As anti-amyloid therapies gain approvals worldwide, the demand for neurological MRI to determine treatment eligibility and monitor ARIA side effects continues to escalate.
“This effort marks a pivotal step in our journey to advance precision care in neurology,” said Roland Rott, President and CEO of Imaging at GE HealthCare. “By integrating icometrix’s AI-powered insights with our advanced imaging technologies, we aim to empower care teams with the clarity and confidence needed to navigate complex neurological conditions.”
The integration of icobrain into GE HealthCare’s MRI portfolio will complement its deep learning tools—such as AIR x Brain, AIR Recon DL, and SONIC DL 3D—to create a more seamless workflow for radiologists. The goal is to manage increasing imaging volumes without sacrificing accuracy or efficiency, particularly as providers monitor Alzheimer’s patients on anti-amyloid therapies.
Kelly Londy, President and CEO of MR at GE HealthCare, emphasized the broader vision: “Along with our commitment to pushing the barriers of neuroscience research with our innovative MRI technology, we’re dedicated to strengthening our neurology portfolio and our MR imaging capabilities to provide advanced solutions to clinicians providing more precise care for patients both now and in the future. Our anticipated acquisition of icometrix and its icobrain solutions supports our goal to help clinicians deliver high-quality, timely care to meet this increased demand in MR technology.”
icometrix CEO Wim Van Hecke highlighted the opportunities created by joining GE HealthCare: “Together, we aim to leverage our complementary technology to address the complexities of managing neurological care.” Beyond clinical adoption, icometrix also collaborates with pharmaceutical companies to support drug development, clinical trials, and real-world evidence programs—further expanding its reach.
For GE HealthCare, the move aligns with its broader neuro solutions ecosystem, which already includes MR and PET scanners, pharmaceutical diagnostics, and digital quantification tools like MIMneuro for amyloid imaging. By adding icometrix’s software, the company aims to provide clinicians with a holistic suite of technologies for diagnosis, monitoring, and treatment planning in neurology.
Financial terms of the acquisition were not disclosed. GE HealthCare stated it plans to fund the deal with cash on hand.